{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:02:40Z","timestamp":1789380160031,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,14]]},"DOI":"10.7759\/cureus.116203","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:05:22Z","timestamp":1789376722000},"source":"Crossref","is-referenced-by-count":0,"title":["Persistent HyperCKemia Beyond Post-Viral Myositis: A Case of Anti-HMGCR Immune-Mediated Necrotizing Myopathy"],"prefix":"10.7759","author":[{"given":"Rita","family":"Xavier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach Y","year":"2020","unstructured":"Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020, 16:689-701. 10.1038\/s41584-020-00515-9","journal-title":"Nat Rev Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen AL","year":"2016","unstructured":"Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016, 374:664-9. 10.1056\/NEJMra1515161","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen AL","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, Casciola-Rosen LA. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011, 63:713-21. 10.1002\/art.30156","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170287","article-title":"Impacts for children living with genetic muscle disorders and their parents - findings from a population-based study","volume":"5","author":"Jones KM","year":"2018","unstructured":"Jones KM, O'Grady G, Rodrigues MJ, Ranta A, Roxburgh RH, Love DR, Theadom A. Impacts for children living with genetic muscle disorders and their parents - findings from a population-based study. J Neuromuscul Dis. 2018, 5:341-52. 10.3233\/JND-170287","journal-title":"J Neuromuscul Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas MC","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015, 372:1734-47. 10.1056\/NEJMra1402225","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez I","year":"2018","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018, 20:21. 10.1007\/s11926-018-0732-6","journal-title":"Curr Rheumatol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-307132","article-title":"Toxic and drug-induced myopathies","volume":"85","author":"Needham M","year":"2014","unstructured":"Needham M, Mastaglia FL. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry. 2014, 85:936-44. 10.1136\/jnnp-2013-307132","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood K","year":"2005","unstructured":"Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005, 173:489-95. 10.1503\/cmaj.050051","journal-title":"CMAJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5770\/cgj.23.463","article-title":"Using the clinical frailty scale in allocating scarce health care resources","volume":"23","author":"Rockwood K","year":"2020","unstructured":"Rockwood K, Theou O. Using the clinical frailty scale in allocating scarce health care resources. Can Geriatr J. 2020, 23:210-5. 10.5770\/cgj.23.463","journal-title":"Can Geriatr J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/2ao5ze","article-title":"Treatment and outcomes in anti-HMG-CoA reductase-associated immune-mediated necrotising myopathy. Comparative analysis of a single-centre cohort and published data","volume":"40","author":"Rademacher JG","year":"2022","unstructured":"Rademacher JG, Glaubitz S, Zechel S, Oettler M, Tampe B, Schmidt J, Korsten P. Treatment and outcomes in anti-HMG-CoA reductase-associated immune-mediated necrotising myopathy. Comparative analysis of a single-centre cohort and published data. Clin Exp Rheumatol. 2022, 40:320-8. 10.55563\/clinexprheumatol\/2ao5ze","journal-title":"Clin Exp Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach Y","year":"2018","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018, 28:87-99. 10.1016\/j.nmd.2017.09.016","journal-title":"Neuromuscul Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge Z","year":"2016","unstructured":"Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016, 280:8-23. 10.1111\/joim.12451","journal-title":"J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner JL","year":"2012","unstructured":"Werner JL, Christopher-Stine L, Ghazarian SR, et al.. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012, 64:4087-93. 10.1002\/art.34673","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan A","year":"2018","unstructured":"Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Aragu\u00e1s E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018, 17:816-28. 10.1016\/S1474-4422(18)30254-0","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328358ac72","article-title":"Therapeutic advances in myositis","volume":"24","author":"Aggarwal R","year":"2012","unstructured":"Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol. 2012, 24:635-41. 10.1097\/BOR.0b013e328358ac72","journal-title":"Curr Opin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes ES","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al.. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015, 36:1012-22. 10.1093\/eurheartj\/ehv043","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000399","article-title":"Statin-associated immune-mediated myopathy: biology and clinical implications","volume":"28","author":"Christopher-Stine L","year":"2017","unstructured":"Christopher-Stine L, Basharat P. Statin-associated immune-mediated myopathy: biology and clinical implications. Curr Opin Lipidol. 2017, 28:186-92. 10.1097\/MOL.0000000000000399","journal-title":"Curr Opin Lipidol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen AL","year":"2015","unstructured":"Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015, 373:1680-2. 10.1056\/NEJMc1506163","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28333","article-title":"Effectiveness and safety of IVIG for the treatment of HMGCR immune-mediated necrotizing myopathy","volume":"71","author":"Suh J","year":"2025","unstructured":"Suh J, Amato AA. Effectiveness and safety of IVIG for the treatment of HMGCR immune-mediated necrotizing myopathy. Muscle Nerve. 2025, 71:392-7. 10.1002\/mus.28333","journal-title":"Muscle Nerve"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan S","year":"2015","unstructured":"Ramanathan S, Langguth D, Hardy TA, et al.. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm. 2015, 2:e96. 10.1212\/NXI.0000000000000096","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/518642-persistent-hyperckemia-beyond-post-viral-myositis-a-case-of-anti-hmgcr-immune-mediated-necrotizing-myopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:05:23Z","timestamp":1789376723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/518642-persistent-hyperckemia-beyond-post-viral-myositis-a-case-of-anti-hmgcr-immune-mediated-necrotizing-myopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.116203","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}